Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2025-02-26 Annual Report
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Annual Report 2024
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2024' for Novozymes A/S, with detailed contents including financial statements, management messages, sustainability statements, corporate governance, remuneration report, and auditor's reports. It contains comprehensive financial data, performance highlights, strategic direction, and sustainability information. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of consolidated financial statements and auditor's reports confirms it is a full annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2024
2025-02-26 English
Earnings Release 2024
Earnings Release Classification · 100% confidence The document contains detailed financial performance metrics for the full year 2024, including pro forma and IFRS figures, segment breakdowns (Food & Health Biosolutions, Planetary Health Biosolutions), key ratios (EBITDA margin, EPS), and a specific outlook for 2025. It also mentions a proposed dividend and a share buyback program. The structure, depth of financial data, and inclusion of a CEO commentary strongly suggest this is a comprehensive report summarizing annual results, rather than just a brief announcement. The presence of a conference call link and detailed tables comparing current year results against the previous year and providing an outlook points towards an Earnings Release (ER) or an Interim/Annual Report. Since the text covers the *full year* (FY 2024) and provides extensive detail, it is more comprehensive than a typical quarterly Earnings Release (ER). However, it is not explicitly labeled as a 10-K. Given the context of providing full-year financial highlights, outlook, and management commentary, it aligns best with a comprehensive Earnings Release or the core financial section often found in an Annual Report. Since it is a detailed summary of results and outlook, and not explicitly the full 10-K filing, 'ER' (Earnings Release) is the most appropriate classification for a detailed results announcement, although it contains more detail than a typical brief ER. If this were the full statutory filing, it would be 10-K. Given the structure, it functions as a detailed Earnings Release/Report Summary. I will classify it as ER, as it is a results announcement, but note the high level of detail. FY 2024
2025-02-26 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 98% confidence The document text describes a major corporate transaction: Novonesis acquiring dsm-firmenich's share of the Feed Enzyme Alliance for EUR 1.5 billion. It details the strategic rationale, financial impact, and includes an announcement for a conference call to discuss the event. This type of announcement, detailing a significant corporate action like an acquisition or major financing, falls under the 'Capital/Financing Update' category (CAP). It is not a standard periodic report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Since it is a detailed announcement of a transaction, it is classified as CAP.
2025-02-11 English
M&A Activity 2025
M&A Activity Classification · 98% confidence The document announces an agreement for Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance for EUR 1.5 billion. This is a significant corporate action involving a merger/acquisition/divestiture. The text explicitly mentions an 'agreement' and refers to an 'attachment' for more details, suggesting it is an announcement rather than the full legal filing. Based on the definitions, this clearly falls under M&A Activity (TAR). The document length is short (1217 chars) and it points to an attachment, reinforcing that it is an announcement of a transaction.
2025-02-11 English
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document explicitly details 'Trading by management and close relations of management' and cites Article 19 of the EU Market Abuse Regulation (MAR). It reports specific transactions (shares received) by an Executive Vice President, including date, volume, and price. This content directly corresponds to the reporting requirements for insider transactions by directors and executives, which maps precisely to the 'Director's Dealing' category.
2025-01-03 English
Director's Dealing 2025
Director's Dealing Classification · 98% confidence The document explicitly discusses 'Trading by management and close relations of management' and cites 'article 19 in Regulation (EU) No 596/2014' (Market Abuse Regulation). This directly relates to insider transactions by directors and executives. The filing type 'Directors' Dealing' (DIRS) is the most appropriate classification. Although the text mentions an attachment and is short, the core content is a specific regulatory disclosure about insider trading, making DIRS more specific than a general RPA or RNS.
2025-01-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.